Balyasny Asset Management’s Astria Therapeutics ATXS Stock Holding History

Balyasny Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,636,921	Closed	-$21.4M	–	2877
2025 Q4	$21.4M	Buy	+1,636,921	New	+$19.6M	0.03%	678
2025 Q2	–	Sell	-28,984	Closed	-$155K	–	2809
2025 Q1	$155K	Buy	+28,984	New	+$203K	﹤0.01%	2636
2024 Q3	–	Sell	-50,776	Closed	-$462K	–	2730
2024 Q2	$462K	Buy	50,776 +13,039	+35%	+$127K	﹤0.01%	2078
2024 Q1	$531K	Buy	+37,737	New	+$470K	﹤0.01%	2023
2023 Q2	–	Sell	-485,939	Closed	-$6.46M	–	2261
2023 Q1	$6.46M	Buy	+485,939	New	+$6.57M	0.02%	972
2018 Q2	–	Sell	-207	Closed	-$22K	–	1769
2018 Q1	$22K	Buy	+207	New	+$20.7K	﹤0.01%	1877

Balyasny Asset Management's ATXS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,636,921 shares — an estimated $21.4M sold.

Balyasny Asset Management first reported a position in ATXS in Q1 2018 and held it in 6 quarters. The position peaked at $21.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Balyasny Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 1,636,921 Astria Therapeutics shares in Q1 2026, an estimated $21.4M.
Balyasny Asset Management first reported a position in Astria Therapeutics in Q1 2018 and held it in 6 quarters.
Balyasny Asset Management's Astria Therapeutics position peaked at $21.4M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.